Bioxbio.com includes the journal factors, ISSN, number of articles and other detailed information of over 11000 journals in different fields. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. In this review, we summarize the clinical trials and discuss challenges and opportunities to accelerate the implementation of precision oncology. With advanced computer data processing capabilities, real-world registries and data mining are expanding. The identification of functional non-coding mutations is a key challenge in the field of genomics. We are pleased to announce that the Translational Cancer Research (TCR) has attained its latest impact factor update for the 2021 citation year: 0.496. Accessibility How Influential is Precision Cancer Medicine? Tamminga M, de Wit S, Hiltermann TJN, et al. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher. CiteScore: 1.9 . 1The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, TX, 2Department of Medical Oncology, Euromedica General Clinic, Thessaloniki, Greece, 3Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UC San Diego Moores Cancer Center, San Diego, CA, USA. Levy, Niall J. Lennon, Viktor A. Adalsteinsson and Stacey B. Gabriel, Jake S. ODonnell, Mark J. Smyth and Michele W. L. Teng, Michael F. Berger and Eliezer M. Van Allen, Tracy L. Stockley, Amit M. Oza, Hal K. Berman, Natasha B. Leighl, Jennifer J. Knox, Frances A. Shepherd, Eric X. Chen, Monika K. Krzyzanowska, Neesha Dhani, Anthony M. Joshua, Ming-Sound Tsao, Stefano Serra, Blaise Clarke, Michael H. Roehrl, Tong Zhang, Mahadeo A. Sukhai, Gabrielle Bertier, Jian Carrot-Zhang, Vassilis Ragoussis and Yann Joly, Tushar Tomar, Steven de Jong, Nicolette G. Alkema, Rieks L. Hoekman, Gert Jan Meersma, Harry G. Klip, Ate GJ van der Zee and G. Bea A. Wisman, Carlota Rubio-Perez, Jordi Deu-Pons, David Tamborero, Nuria Lopez-Bigas and Abel Gonzalez-Perez, Andrew E. Teschendorff, Shijie C. Zheng, Andy Feber, Zhen Yang, Stephan Beck and Martin Widschwendter, Jordi Serra-Musach, Francesca Mateo, Eva Capdevila-Busquets, Gorka Ruiz de Garibay, Xiaohu Zhang, Raj Guha, Craig J. Thomas, Judit Grueso, Alberto Villanueva, Samira Jaeger, Holger Heyn, Miguel Vizoso, Hector Prez, Alex Cordero, Eva Gonzalez-Suarez, Manel Esteller, PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories, Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Retinoic acid and TGF- signalling cooperate to overcome MYCN-induced retinoid resistance, Longitudinal analysis of treatment-induced genomic alterations in gliomas, 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets, Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations, Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine, iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes, Looking beyond the cancer cell for effective drug combinations, Somatic cancer variant curation and harmonization through consensus minimum variant level data, A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma, Approaches to modernize the combination drug development paradigm, Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer, Integrating cancer genomic data into electronic health records, Technological considerations for genome-guided diagnosis and management of cancer. Cookies policy. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values. Hence, it can provide a rough estimation only. IS 2021 of Precision Cancer Medicine is 0.34. Cancer Research; Science Translational Medicine; Journal Of Neuroscience; AAPS Journal; AAPS Pharmscitech; Academic Emergency Medicine; Academic Radiology; Accounting and . The management of our journal is a collaborative endeavor by the whole editorial team, featuring an active, widely respected, diverse, and representative Editorial Board. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children, Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match, A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia, The molecular genetics of Philadelphia chromosome-positive leukemias, Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400, Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. The ISSN of Precision Cancer Medicine journal is 26172216. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study, Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial, Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study, Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial, The BATTLE trial: personalizing therapy for lung cancer, Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Cancer Medicine - Wiley Online Library Precision Cancer Medicine is published by AME Publishing Company, The Official Publication of Fudan University Shanghai Cancer Center. It is published by AME Publishing Company. CAR T-cells are a type of adoptive T-cell therapy in which autologous T-lymphocytes are genetically engineered to recognize the antigens expressed on malignant cells.95 Adoptive T-cell therapy has resulted in remarkably high rates of durable CR in hematologic malignancies, including in patients with refractory disease. Wiley The https:// ensures that you are connecting to the Long GV, Stroyakovskiy D, Gogas H, et al. Links to Cancer Journals | OncologyPRO - ESMO Specialty Chief Editor. MITPress. The latest impact factors list will release in june 2023. Genomic studies have revealed that tumors are significantly heterogeneous and complex and therefore optimized therapy does not often result from classical clinical research and practice models. The mix of unsolicited and invited submissions. CAR T-cells are currently being evaluated in solid tumors.96,97. Targeted Oncology | Home - Springer The timely changed papers number can highlight the development tendency of a research field from the bibliometric perspective. Le Tourneau C, Delord JP, Goncalves A, et al. Abd Elmageed ZY, Yang Y, Thomas R, et al. You are using a browser version with limited support for CSS. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm, https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635276.htm, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel, https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer, 27% of 66 matched pts had a PFS2/PFS1 ratio. You can start . The editorial structure of the journal is listed as below and the roles and responsibilities of the editorial team are available at: https://www.amegroups.com . Schwaederle M, Parker BA, Schwab RB, et al. PCM has formed an internationalized editorial board of 211 members from 18 countries, and published 40 articles of authors from 14 countries. This Journal is the 401 st out of 1,172 Nursing journals. 7/12/2019, at, Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. The investigators demonstrated that CTC monitoring was a robust and meaningful response endpoint for early-phase clinical trials in this setting.49. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journals documents. Impact factor (IF) is a scientometric factor based on the yearly average number of citations on articles published by a particular journal in the last two years. The overall rank of Precision Cancer Medicine is 17687. and JavaScript. But, as some people with cancer are already finding out, there is another way. Arlene S. Bierman, Bridget T. Burke, Leeann N. Comfort, Maya Gerstein, Nora M. Mueller, Craig A. Umscheid. However, the biological significance of this observation for carcinogenesis is unclear given that most o Cancer patients often show no or only modest benefit from a given therapy. Beyond genomics, RNA and protein profiling, with proteins being the effectors of signaling, also appear to be important in mediating biologic impact. Precision Cancer Medicine has an h-index of 3. Two drug approvals by the FDA were based, at least in part, on such data: pembrolizumab for any solid tumor with a mismatch repair gene defect (https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm) and palbociclib for male breast cancer (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635276.htm). Such cellular evolution involves the interplay of advantageous driver lesions, neutral or passenger/hitchhiker abnormalities, molecular changes in the tumor cells that increase the rate of other genomic anomalies, and modifications to the microenvironment and immune machinery that alter the fitness effects of other variables.119 Strategies to address tumor complexity include targeting self-renewing cancer stem cells to overcome their plasticity and adaptability, impacting the microenvironment, and turning cancer into a chronic disease (using cytostatic drugs to suppress cell division and new mutations). 3. Jennings LJ, Arcila ME, Corless C, et al. The RNA and protein landscape that could bring precision medicine to more people, Health-care inequality could deepen with precision oncology, The gene-therapy revolution risks stalling if we dont talk about drug pricing, Unleashing the power of big data to guide precision medicine in China, Early prediction of preeclampsia in pregnancy with cell-free RNA, Patterns of tumour transcriptional variability, In situ tumour arrays reveal early environmental control of cancer immunity, Pan-KRAS inhibitor disables oncogenic signalling and tumour growth, Why the world needs more transparency on the origins of novel pathogens, A fat-blocking drug could help to fight metastatic cancer. npj Precision Oncology - Nature Michuda J, Igartua C, Taxter T, Bell JS, Pelossof R, White K. Transcriptome-based cancer type prediction for tumors of unknown origin. Primary lung secretory carcinoma: a case report, Trastuzumab-Pertuzumab resistance in a case of HER2-del16 expressing colorectal cancera case report. Frontiers in Medicine Results 3.1. Von Hoff DD, Stephenson JJ Jr., Rosen P, et al. ESMO Open: First Official Impact Factor of 5.329 Hainsworth JD, Meric-Bernstam F, Swanton C, et al. . An International Standard Serial Number (ISSN) is a unique code of 8 digits. The majority of these trials2,3,12,24 have shown improvement in clinical outcomes when treatments are matched to drugs compared to when they are not. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. The rapidly expanding body of knowledge about the roles of genomics and the immune system in cancer has enabled the development of therapies targeted to specific molecular alterations or other biologic characteristics, such as those implicated in immune suppression. We extend such ana Molecular characterization has the potential to advance the management of pediatric cancer and high-risk hematologic disease. BMC Cancer | About - BioMed Central AR-V7 and treatment selection in advanced prostate cancer: are we there yet? A plethora of first- and second-generation precision medicine trials have since been conducted (Tables 1 and and2).2). The best quartile for this journal is Q3. Through this web page, researchers can check the impact factor, total citation, journal quartile, and journal aim & scope. More 3-Year IF Trend, Prediction, Ranking, Key Factor Analysis. Inclusion in an NLM database does not imply endorsement of, or agreement with, The British Journal of Cancer . Some solutions provided by trials with higher matching rates, e.g., I-PREDICT12 (matching rate, 49%), include: (i) use of clinical trial navigators and medication acquisition specialists; (ii) application of a large NGS panel with >200 genes; (iii) creation of just-in-time electronic molecular tumor boards immediately upon physician request; and (iv) exploitation of biomarkers to match patients to chemotherapy, hormonal therapy, and immunotherapy (in addition to gene-targeted agents). Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative, Personalized vaccines for cancer immunotherapy. Seminars The journal welcomes manuscripts in . Garassino M, Rodriguez-Abreu D, Gadgeel S, et al. Other investigators have also used transcriptomics to select targeted treatments in patients with advanced solid tumors.57,58 Challenges that prevent extensive use of transcriptomic biomarkers are degradation and fragmentation of RNA in formalin-fixed, paraffin-embedded tissue samples, complexity of required bioinformatic analysis of profiling data and low reproducibility of the results. Your US state privacy rights, Annals of Oncology The official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology (JSMO). Validation of database information can be performed by comparing outcomes of clinical trials that led to approval with those in the database; if outcomes are similar, real-world data can then be used to rapidly predict new applications for medicines. In 2001, the human genome was sequenced.33 Although this milestone represented an arduous and tremendously expensive endeavour, both the price and time required for sequencing have decreased precipitously, with technology advancing in a manner unparalleled in human history. Genome Medicine 2016 8 :108. Top 100 Journals With Impact Factor in 2022 (Highest To Lowest) This is despite the increasingly clear patient benefit from precision medicine 1, 2, 3, and considerable concomitant interest from patients and payors. ISSN (Online) 2045 . Coverage history of this journal is as following: 2018-2021. As a service to our customers we are providing this early version of the manuscript. The complicated nature of tumor biology is also the result of interactions between the tumor, host, and local ecosystem, including HLA type, genetic polymorphisms, microbiome, immune cell repertoire, and tumor microenvironment.120 New strategies, some of which now have a proven track record, include gene-directed therapies and a host of immune-targeted approaches (e.g., checkpoint blockade, CAR T-cells, personalized vaccinomics).120,121. The rise of genomically targeted therapies and immunotherapy has revolutionized the practice of oncology in the last 1015 years. In the meantime, to ensure continued support, we are displaying the site without styles Krop IE, Jegede O, Grilley-Olson JE, et al. This Journal is the 314 th out of 471 Oncology journals. Genomic biomarkers have been the most successful to date, but other biomarkers, including protein assays and transcriptomics, are being developed and tested.13,24,25 Several molecular alterations have been identified using sequencing and high-throughput technologies and have led to the approval of targeted agents by the Food and Drug Administration (FDA).26,27 Importantly, in recent years, the precision medicine paradigm has embraced immunotherapy and its interaction with genomics, as genomic characteristics, such as mismatch repair gene defects, are critical predictors of checkpoint blockade response.2830. Data Source: Scopus, Explore, visually communicate and make sense of data with our, Metrics based on Scopus data as of April 2023, Biochemistry, Genetics and Molecular Biology. China Personalized Medicine: Recent Progress in Cancer Therapy - MDPI of scholarly journals that accounts for both the number of citations In this post, apart from Frontiers in Medicine Impact Factor, I have tried to compile all the necessary . Journal Impact - Bioxbio Cambridge Prisms: Precision Medicine | Cambridge Core Precision medicine (PM) can be defined as a predictive, preventive, personalized, and participatory healthcare service delivery model. Get the most important science stories of the day, free in your inbox. About | Precision Clinical Medicine | Oxford Academic